Fermenta Biotech Limited’s Active Pharmaceutical Ingredient (API) manufacturing facility situated at Dahej, Gujarat, India has received a certificate of GMP compliance from the Competent Authority of Germany, following a European Union Good Manufacturing Practice (EU GMP) inspection that was conducted in March 2024. This approval reflects Company’s unwavering commitment that the Quality Assurance is in compliance with the stringent guidelines of Good Manufacturing Practices.
Mr. Prashant Nagre, Managing Director of Fermenta, commented on the occasion, “We are pleased with the positive outcome of the recent EU GMP inspection at our Dahej Manufacturing Facility in Gujarat. The certificate of GMP compliance underscores our commitment to global standards of quality, compliance and consistency in manufacturing.”
About Fermenta Biotech Limited (FBL):
Founded in 1951, Fermenta Biotech Limited (FBL) possesses a growing portfolio of nutrition including Customized Premixes, Fortified Rice Kernel (FRK) and other nutritional ingredients. Apart from its nutrition portfolio, FBL is the only manufacturer of Vitamin D3 in India and a leading global player. It caters to over 350 customers across 60 countries with a worldwide distribution network for a variety of applications such as pharmaceuticals, dietary and nutritional supplements, food, animal nutrition and rodenticides. FBL’s manufacturing facilities in Kullu and Dahej are certificated by global accreditations and its world class R&D centre is located at Thane. FBL also possesses expertise in integrated biotechnology such as enzymes for antibiotic synthesis, other niche APIs and environmental solutions.
For more information about the Company and its businesses, please visit our website www.fermentabiotech.com
Safe Harbor :
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.